Similar articles

• Recurrent Candida albicans endophthalmitis in an immunocompromised host.

  Weinstein O, Levy J, Lifshitz T. Weinstein O, et al. Can J Ophthalmol. 2007 Feb;42(1):154-5. Can J Ophthalmol. 2007. PMID: 17361271 No abstract available.
• The effects of caspofungin and voriconazole in experimental Candida endophthalmitis.

  Kusbeci T, Avci B, Cetinkaya Z, Ozturk F, Yavas G, Ermis SS, Inan UU. Kusbeci T, et al. Curr Eye Res. 2007 Jan;32(1):57-64. doi: 10.1080/02713680601107157. Curr Eye Res. 2007. PMID: 17364736
• Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.

  Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Breit SM, et al. Am J Ophthalmol. 2005 Jan;139(1):135-40. doi: 10.1016/j.ajo.2004.08.077. Am J Ophthalmol. 2005. PMID: 15652837
• Endophthalmitis caused by Phialophora verrucosa: a case report and literature review of Phialophora ocular infections.

  Campos-Herrero MI, Tandón L, Horcajada I, Medina-Rivero F. Campos-Herrero MI, et al. Enferm Infecc Microbiol Clin. 2012 Mar;30(3):163-5. doi: 10.1016/j.eimc.2011.10.012. Epub 2012 Jan 31. Enferm Infecc Microbiol Clin. 2012. PMID: 22296814 Review. No abstract available.
• Candida endophthalmitis: focus on current and future antifungal treatment options.

  Khan FA, Slain D, Khakoo RA. Khan FA, et al. Pharmacotherapy. 2007 Dec;27(12):1711-21. doi: 10.1592/phco.27.12.1711. Pharmacotherapy. 2007. PMID: 18041891 Review.